969 results on '"Kerbel, Robert S."'
Search Results
202. Modeling Therapy of Late or Early‐Stage Metastatic Disease in Mice
203. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models
204. Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers
205. Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma
206. Therapy-activated stromal cells can dictate tumor fate
207. Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer
208. Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy
209. Interleukin 12: newest member of the antiantiogenesis club
210. Metronomic Chemotherapy: Possible Clinical Application in Advanced Hepatocellular Carcinoma1
211. Mouse Models of Advanced Spontaneous Metastasis for Experimental Therapeutics
212. Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer
213. Development of Patient Derived Xenograft Models of Overt Spontaneous Breast Cancer Metastasis: A Cautionary Note
214. Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect
215. Metronomic chemotherapy for triple negative breast cancer?
216. Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma
217. Exploiting drug repositioning and the brain microenvironment to treat brain metastases
218. Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy
219. Abstract IA22: Preclinical modeling of adjuvant and metastatic antiangiogenic therapy: Relevance for better predicting clinical outcomes
220. Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer
221. Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration‐Resistant Prostate Cancer
222. Tumor progression in metastasis: an experimental approach using lectin resistant tumor variants
223. On a possible epigenetic mechanism(s) of tumor cell heterogeneity: The role of DNA methylation
224. Immunology of metastasis: Can the immune response cope with disseminated tumor?
225. Vessel co-option in cancer
226. Chemotherapy counteracted: resistance of tumour cells to chemotherapy can severely affect the efficacy of this anticancer treatment. The non-tumour cells of the organ in which the tumour resides may aid the emergence of such resistance
227. The inhospitable host?
228. Abstract 4124: Potent anti-tumor and metastatic breast cancer efficacy of bevacizumab with CRLX101, an investigational chemotherapy nanoparticle-drug conjugate that secondarily suppresses HIF-1α
229. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment
230. Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma
231. Effect of the timing of sunitinib administration on the predictive value of biomarkers in renal cell cancer (mRCC).
232. Rationale for metronomic chemotherapy in phase III trials
233. PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
234. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib
235. Impact of Metronomic UFT/Cyclophosphamide Chemotherapy and Antiangiogenic Drug Assessed in a New Preclinical Model of Locally Advanced Orthotopic Hepatocellular Carcinoma1
236. Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer
237. Abstract 3142: Derivation and analysis of preclinical models of human her-2 positive breast cancer
238. [8] Detection of Fc receptors
239. Analysis of Growth, Selection, and Metastasis of Tumor Cell Populations In Vivo Using Random Insertions of Foreign DNA as Genetic Tags
240. Tumor specific antigens induced by mutagens and DNA hypomethylating agents: implications for the immunobiology of neoplasia
241. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
242. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
243. Metronomic Antiangiogenic Chemotherapy: Questions and Answers
244. Oncogenes and Tumor Angiogenesis
245. Fc Receptor Heterogeneity as a Marker for Lymphoid and Myeloid Cell Differentiation
246. Metronomic Chemotherapy for Treatment of Metastatic Disease: From Preclinical Research to Clinical Trials
247. Targeting Oncogenes in Pediatric Malignancies
248. Metronomic Low-Dose Antiangiogenic Chemotherapy in Mice and Man
249. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer
250. Anti-VEGF therapy reduces intestinal inflammation in Endoglin heterozygous mice subjected to experimental colitis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.